|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Insight: Gastric Cancer
Datamonitor, Sep 2010, Pages: 204
Introduction
Despite advances in surgery and the use of multimodality therapy, survival outcomes remain poor for gastric cancer patients. There is an urgent need for more effective therapies to improve survival rates in patients presenting with both localized and advanced disease. The recent approval of Herceptin (trastuzumab; Roche/Chugai) may pave the way for the introduction of more novel drugs
Scope
-Analysis of the gastric cancer market based on a survey of 180 oncologists and GI specialists, supported by interviews with key opinion leaders
-Epidemiologic forecast of the gastric cancer patient populations in the seven major pharmaceutical markets
-In-depth analysis of treatment patterns, regimens prescribed and treatment outcomes for gastric cancer patients
-Discussion of unmet needs and overview of late-stage pipeline drugs
Highlights
Despite a declining trend in incidence rates, the total incidence of gastric cancer in the seven major pharmaceutical markets is forecast to increase over the next decade, driven by the aging populations in these countries. The number of incident cases is forecast to reach over 250,000 cases by the end of 2020.
Because most patients with localized gastric cancer suffer a recurrence, survival is modest for patients with resectable disease. The best outcomes are seen in Japan, where relapse rates are lower compared with the West. In unresectable gastric cancer, survival is very poor and metastatic patients rarely live for more than 1–1.5 years.
There are currently five drugs in company-sponsored Phase III development for advanced gastric cancer, all of which are molecular targeted therapies. While the extent to which these agents will improve patient outcomes remains to be seen, physicians are generally optimistic about the incorporation of these drugs into treatment.
Reasons to Purchase
-Understand prescribing trends in the gastric cancer market
-Examine unmet need within the gastric cancer market and identify opportunities for new product development
-Enhance commercial positioning by increasing understanding of current dynamics within the gastric cancer market
Customers who bought this item also bought
Stakeholder Opinions: Pancreatic Cancer - Gemzar Dominance will Continue among High Levels of Persistent Unmet Needs
Gastric Cancer Drug Discoveries: What the Future Holds
Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011
Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic gastrointestinal cancers represent a significant commercial opportunity due to a lack of approved drugs
Omnitarg (Breast Cancer) - Analysis and Forecasts to 2020
Prostate Cancer Therapeutics - Global Strategic Business Report
The 2011 ASCO (American Society of Clinical Oncology) Annual Meeting - Post Conference Review and Analysis
Pancreatic Cancer Drugs - Global Strategic Business Report
Afinitor (Breast Cancer) - Analysis and Forecasts to 2020
Taxol (Breast Cancer) - Analysis and Forecasts to 2020
|
|
|
|
